Related Experiment Video
Updated: Oct 25, 2025

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
Published on: August 7, 2017
Functional connectivity and cognitive changes after donepezil treatment in healthy participants
P Péran1, A S Salabert2, T Dondaine3
1Toulouse NeuroImaging Center (ToNIC), Université de Toulouse, INSERM, UPS, 31024, Toulouse Cedex 3, France. patrice.peran@inserm.fr.
Rationale:
Donepezil is a potent, noncompetitive, reversible, clinically effective acetylcholinesterase inhibitor. The effects of this drug on healthy brains have seldom been investigated.
Objectives:
The primary objective of the present study was to identify possible functional connectivity markers of the effect of donepezil in healthy young adult volunteers.
Methods:
The study had a double-blind, randomized, crossover design. 30 healthy adult volunteers underwent resting-state MRI scans during 15 days of donepezil or placebo treatment, in accordance with the design.
Results:
Results showed significant differences in intrinsic functional connectivity between donepezil and placebo, mainly in the right executive control network (RECN). More specifically, we found a decrease in the connectivity of the right inferior parietal node with other RECN nodes. Analysis using the cingulate cortex and parahippocampal regions as seeds also revealed complex modulation of functional connectivity in the donepezil condition.
Conclusions:
In conclusion, donepezil treatment for 15 days may result in reorganization of resting-state networks, compared with placebo.
More Related Videos
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
Related Concept Videos
Alzheimer's Disease: Treatment
Cognitive Development During Adulthood
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...